Company
Every investor coverage indicates participated in a round Spark Therapeutics raised.
The transaction that ended Spark Therapeutics's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Roche Group | Acquisition | 2019 | - | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Spark Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Steven M. Altschuler | Board Chair (former) · Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Spark Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-disease drug developer Azura Ophthalmics has appointed healthcare biotech veteran Steven Altschuler, a Ziff Capital Partners managing director and Spark Therapeutics co-founder, as chair of its board.